Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy. (PubMed, Neuropharmacology) - Jun 21, 2024 - "Maintenance therapy with buprenorphine and methadone is the gold standard pharmacological treatment for opioid use disorder (OUD). Together, these data indicate that cebranopadol is highly efficacious in attenuating opioid self-administration and stress-induced reinstatement, while having limited abuse liability properties. Overall, the data suggest clinical potential of this compound for OUD treatment."
Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse
|
|
Federica Benvenuti; Friedbert Weiss; Hongwu Li; Laura Soverchia; Nazzareno Cannella; Qianwei Shen; Rajesh Narendran; Roberto Ciccocioppo; Veronica Lunerti
|